Patient P-01671

Synthetic patientNBL-101 · Day 109 · 45–54 · M · baseline S04Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Improving

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Declining

Discontinuation risk

24%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S04
Day 46 SC-12 recommended — Supportive Compound SC-12
Day 47 Patient accepted — Started SC-12 in the companion
Day 53 GI symptom burden −17% vs expected — Supportive Compound SC-12
Day 59 Tolerance state changed — Unstable → Improving

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days

GI instability+15
Inflammatory activity+6
Nutritional resilience-5
Toxicity-4
Treatment adherence+2

What helped?

Supportive Compound SC-12Day 46
Result: symptom burden −17%

LIFE OS recommendation

No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

18.2/100

worsening · +1.0 vs previous 14 d

Toxicity

Blood

4.3/100

worsening · +6.8 vs previous 14 d

Sleep quality

Wearable

70.8/100

stable · +0.7 vs previous 14 d

Energy level

Daily log

7.7/10

worsening · -0.4 vs previous 14 d

Stress level

Daily log

4.2/10

worsening · +0.5 vs previous 14 d

Steps

Wearable

7,987

worsening · -483 vs previous 14 d

Adherence

Companion

99.1 %

improving · +6.3 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 94 from the failing basin, 12 from restoration.

Would help

No untried action with strong evidence. Compose one from primitives.

Would not help

Nothing clearly counter-productive in the record.

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
-1.5no signal · 42%
Spicy / capsaicin
+0.9no signal · 22%
Insoluble fibre
-0.4no signal · 15%
Dietary fat load
-0.2no signal · 15%
Alcohol
+0.1no signal · 15%
Simple carbohydrates
0no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer

DNA

Fictional pharmacogenomic panel

CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 4.4 · butyrate capacity 49/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 55 ms
Sleep: 8.0 h
Steps: 8,109
Resting HR: 55 bpm

Daily log: GI score 18, nutritional resilience 70, adherence 99.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Keep fibre steady; no new sources this week
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01439	47%	S18	ME-01	improved	79
P-01625	47%	S06	SC-12	improved	83
P-01467	46%	S09	HY-01	improved	79
P-01654	46%	S08	CR-01	improved	85
P-01796	46%	S09	SC-12	improved	86
P-01329	45%	S08	BR-03	improved	79
P-01495	41%	S07	BR-03	improved	85
P-01763	41%	S16	ME-01	improved	100
P-01791	41%	S06	ME-01	improved	79
P-01798	40%	S08	NP-02	improved	78
P-01479	39%	S15	DT-01	improved	84
P-01503	37%	S15	ME-01	improved	80